AIHealthcare

Valence Labs is Recursion’s AI research engine, focused on applying machine learning and computational methods to predict, explain, and decode biology for drug discovery. It originated as Valence Discovery and was acquired by Recursion Pharmaceuticals in May 2023; it now operates as a semi-autonomous research organization within Recursion rather than as an independently funded company. Its market position is in AI-enabled drug discovery and generative chemistry, with a research focus on advancing computational approaches for molecular discovery and validation in real-world drug-discovery pipelines.